Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours

TA86 Gastrointestinal stromal tumours - imatinib: review decision - October 2013 information

TA86 Gastrointestinal stromal tumours - imatinib: Appendix A - decision paper presented to the Institute's Guidance Executive

TA86 Gastrointestinal stromal tumours - imatinib: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 109 KB)

TA86 Gastrointestinal stromal tumours - imatinib: review proposal information

TA86 Imatinib for gastrointestinal stromal tumours: Appendix A - provisional matrix of stakeholders

TA86 Imatinib for gastrointestinal stromal tumours: Appendix A - provisional matrix of stakeholders (PDF 102 KB)

TA86 Imatinib for gastrointestinal stromal tumours: Appendix B - proposal paper presented to the Institute's Guidance Executive

TA86 Imatinib for gastrointestinal stromal tumours: Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 467 KB)

Review decision, February 2008 information

Review decision, February 2007 information

Review proposal, October 2007 information

Appendix A - matrix of consultees and commentators

Appendix A - matrix of consultees and commentators (PDF 49 KB)

TA86 Gastrointestinal stromal tumours - imatinib: review proposal information

TA86 Gastro-intestinal stromal tumours (GIST) - imatinib: distribution list 

TA86 Gastro-intestinal stromal tumours (GIST) - imatinib: distribution list (PDF 20 KB)

Assessment report 

Final Appraisal Determination: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours information

Gastrointestinal stromal tumours - imatinib: assessment report 

Agenda and attendee list for the Appraisal Committee Meeting held on Thursday 22nd April

Protocol: Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours

Scope: Imatinib for gastrointestinal stromal tumours

2003/009 NICE asked to develop guidance on treating eczema, support programmes for parents dealing with conduct disorder in children, use of statins for heart disease, and when hysterectomy is appropriate information